Patent application number | Description | Published |
20110256093 | Treating Disorders Associated with IL-20 Receptor-Mediated Signaling Pathway by Blocking IL-20 Receptor Activity - Treating a disorder (e.g., osteoporosis, renal failure, or diabetic nephropathy) associated with a signaling pathway mediated by IL-20 receptor with an agent that suppresses IL-20 receptor activity, e.g., an antibody that neutralizes IL-20 receptor via binding to IL-20R1, an antisense nucleic acid that suppresses expression of IL-20R1, a small molecule that inhibits IL-20 receptor activity, or a dominant negative mutant of IL-19, IL-20, or IL-24. | 10-20-2011 |
20130216534 | USE OF IL-20 ANTAGONISTS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS - The invention features methods and compositions for preventing or treating rheumatoid arthritis and osteoporosis by administering an antagonist of IL-20. The IL-20 antagonist may be an anti-IL-20 antibody, such as mAB 7E, that is capable of binding human IL-20 and blocking IL-20 interaction with its receptors. | 08-22-2013 |
20130315893 | HUMANIZED ANTI-IL-20 ANTIBODY AND USES THEREOF - The present disclosure provides humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure. | 11-28-2013 |
20140023648 | Treatment of Osteoarthritis Using IL-20 Antagonists - Methods for alleviating or delaying the onset of osteoarthritis in a subject in need of the treatment using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20, e.g., an anti-IL-20 antibody. | 01-23-2014 |
20140044715 | TREATING ALLERGIC AIRWAY DISORDERS USING ANTI-IL-20 RECEPTOR ANTIBODIES - Treatment of an allergic airway disorder (e.g., asthma or bronchial airway obstruction) using anti-IL-20R1 antibodies such as mAb51D, mAb7GW, or functional variants thereof. | 02-13-2014 |
20140056886 | Humanized Anti-IL-20 Antibody And Uses Thereof - Humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure. | 02-27-2014 |
20140065144 | USE OF IL-20 ANTAGONISTS FOR PROMOTING BONE FRACTURE HEALING - Promoting bone fracture healing in a subject having a bone fracture using an IL-20 antagonist, which can be an antibody that blocks an IL-20-mediated signaling pathway. Such antibodies include anti-IL-20 antibodies and anti-IL-20R1 antibodies capable of blocking the IL-20-mediated signaling pathway. | 03-06-2014 |
20140120094 | Use of IL-20 Antagonists for Treating Liver Diseases - Reducing liver fibrosis in a subject having or being suspected of having a liver disease using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway. | 05-01-2014 |
20140370014 | USE OF IL-20 ANTAGONISTS FOR ALLEVIATING OBESITY - Alleviating obesity in a subject (e.g., a human subject) having, being suspected of having, or at risk for obesity using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway. | 12-18-2014 |
20140370015 | USE OF IL-20 ANTAGONISTS FOR ALLEVIATING SPINAL CORD INJURY - Alleviating neural injury, such as spinal cord injury, in a subject (e.g., a human subject) in need of the treatment using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway. | 12-18-2014 |